Eli Lilly and Co.’s Animal Division reported worldwide revenue of $264.1 million in the first quarter ended March 31, an increase of 12 percent over the year-ago period. U.S. revenue grew by 43 percent, to $153.6 million, primarily due to sales from the Posilac acquisition completed in October. Revenue outside the U.S. fell by 13 percent, to $110.5 million, primarily because of unfavorable exchange rates, according to the Indianapolis company. Overall, Lilly reported first-quarter net income of $1.3 billion on revenue of $5 billion, compared to $1.1 billion and $4.8 billion, respectively, in the year-ago period. <HOME>
